Search - tctmd.com

Displaying 1 - 20 of 467

Sort: Relevancy | Date

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

Presentation TCT 2016

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David Hildick-Smith

November 02, 2016

Presentation TCT 2016

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David R. Holmes Jr.

November 02, 2016

Presentation TCT 2016

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Presenter: Martin B. Leon, Louis A. Cannon, Sean P. Lyden

November 02, 2016

Presentation TCT 2016

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Andreas Baumbach

November 01, 2016

Presentation TCT 2016

What Should Be the Next Series of Clinical Trials in PFO Closure?

Presenter: Eustaquio Maria Onorato, Richard Smalling, John D. Carroll

November 01, 2016

Presentation TCT 2016

What Do the Randomized Clinical Trials Tell Us and How Did the FDA Respond?

Presenter: John D. Carroll, Christian Spies

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Accurate: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Helge Möllmann

November 01, 2016

Presentation TCT 2016

Direct Flow: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Azeem Latib

November 01, 2016

Presentation TCT 2016

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Ted Feldman

November 01, 2016

Presentation TCT 2016

Portico: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Raj Makkar

November 01, 2016

Presentation TCT 2016

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Jeffrey J. Popma

November 01, 2016

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Presentation TCT 2016

Featured Lecture: Balancing the Needs for Data Transparency and the Clinical Trial Enterprise

Presenter: Robert O. Bonow, Mitchell W. Krucoff, Manesh R. Patel

November 01, 2016

Presentation TCT 2016

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

Presenter: Fernando Alfonso, Ran Kornowski, Pieter R. Stella

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Advertisement

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

What Should Be the Next Series of Clinical Trials in PFO Closure?

What Do the Randomized Clinical Trials Tell Us and How Did the FDA Respond?

To Pretreat or Not to Pretreat? The DUBIUS Trial

Accurate: Design Features, Special Attributes, and Clinical Trial Program

Direct Flow: Design Features, Special Attributes, and Clinical Trial Program

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Portico: Design Features, Special Attributes, and Clinical Trial Program

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Featured Lecture: Balancing the Needs for Data Transparency and the Clinical Trial Enterprise

Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial: 6-Month Angiographic and 1-Year Clinical Follow Up

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content